Amcor (Australia) has made an offer of $2025 million for parts of Alcan Packaging (France), including the company's global pharmaceuticals division.
Amcor (Australia) has made an offer of $2025 million for parts of Alcan Packaging (France), including the company's global pharmaceuticals division. Alcan is currently a part of Rio Tinto, a mining group headquartered in the UK. Rio Tinto has acknowledged the offer and will respond following consultation with European works councils; however, in a statement the company has already said: "We believe Amcor's offer is in the interests of all stakeholders. These businesses would be acquired by a leading player in the global packaging sector that is well placed to enable ongoing success."
Amcor is also confident that the acquisition is a recipe for success. A statement from the company explained that the acquisition will allow it to provide broader offerings and enhanced customer service. "Critically, beyond the hard assets, the combined company will draw on the best people from both organizations to drive these improvements," Ken MacKenzie, Amcor's Managing Director and CEO, added in a statement from Amcor.
Amcor has offered to acquire four divisions of Alcan: global pharmaceuticals, food Europe, Food Asia and global tobacco. The divisions will provide Amcor with 80 plants across 24 countries, as well as 14000 employees, and are expected to add approximately $4.1 billion in sales.
In a separate statement issued by Amcor's healthcare division, Bob Biasi, Vice President Technology at Amcor Flexibles Healthcare, added: "Alcan Packaging has a strong history of creating high-performance products, as does Amcor. The combined business will provide customers with better solutions faster."
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.